Source: Eur Respir J 2009; 34: 948-957
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Zhao L., Sebkhi A., Ali O., Wojciak-Stothard B., Mamanova L., Yang Q., Wharton J., Wilkins M. R.. Simvastatin and sildenafil combine to attenuate pulmonary hypertension. Eur Respir J 2009; 34: 948-957

Member's Comments

No comment yet.

Related content which might interest you: Fasudil reduces monocrotaline-induced pulmonary arterial hypertension: comparison with bosentan and sildenafil Source: Eur Respir J 2010; 36: 800-807 Year: 2010 Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension Source: Eur Respir J 2007; 29: 469-475 Year: 2007 Improvement of exercise capacity in monocrotaline induced pulmonary hypertension by the phosphodiesterase inhibitor Vardenafil Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals Year: 2006 Human apyrase (APT102) treatment attenuates the development of severe pulmonary arterial hypertension (PAH) Source: Annual Congress 2013 –Pulmonary circulation: animal models and experimental treatments Year: 2013 Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension Source: Eur Respir J 2004; 24: 1007-1010 Year: 2004 Hemodynamic effects of sildenafil in pulmonary arterial hypertension (PAH) patients Source: Annual Congress 2005 - Treatment of pulmonary arterial hypertension Year: 2005 Hemodynamic and anti-remodelling effect of the Rho kinase inhibitor Y-27632 in the monocrotaline pulmonary arterial hypertension rat model Source: International Congress 2016 – The nature of pulmonary hypertension Year: 2016 Combining bosentan and sildenafil improves mitochondrial capacity and restores right ventricular contractility in established pulmonary hypertension Source: Annual Congress 2007 - Pathogenesis and novel therapeutic targets in pulmonary hypertension Year: 2007 Targeting aquaporin 1 reverses hypoxia-induced pulmonary hypertension in mice Source: International Congress 2016 – The nature of pulmonary hypertension Year: 2016 Effect of POL6014, a protein epitope mimetic (PEM) neutrophil elastase inhibitor, in a model of monocrotaline (MCT)-induced pulmonary arterial hypertension in rats Source: Annual Congress 2013 –Pulmonary circulation: animal models and experimental treatments Year: 2013 Dexamethasone reverses monocrotaline-induced pulmonary arterial hypertension in rats Source: Eur Respir J 2011; 37: 813-822 Year: 2011 Early atorvastatin administration suppresses the oxygen-activating ability of rat neutrophils during monocrotalinin-induced pulmonary arterial hypertension (PAH). Source: Virtual Congress 2020 – Experimental approaches to pulmonary hypertension Year: 2020 Blunted effects of rho-kinase inhibitor, fasudil, on pulmonary arterial pressure in Yak, a high altitude-adapted animal Source: Annual Congress 2013 –Pulmonary circulation: animal models and experimental treatments Year: 2013 Goal-oriented treatment and combination therapy for pulmonary arterial hypertension Source: Eur Respir J 2005; 26: 858-863 Year: 2005 Long-term effects of bosentan in patients with HIV-associated pulmonary arterial hypertension Source: Eur Respir J 2009; 33: 92-98 Year: 2009 Hemodynamical effects of metformin and sildenafil in the treatment of experimental pulmonary hypertension Source: International Congress 2019 – Pulmonary hypertension: clinical Year: 2019 Enhanced efficacy of combining imatinib with sildenafil in a rodent model of pulmonary arterial hypertension Source: Annual Congress 2010 - Experimental pulmonary hypertension Year: 2010 Bosentan combined with sildenafil prevents right ventricular hypoxia in pulmonary arterial hypertension Source: Annual Congress 2008 - Pathophysiology of pulmonary hypertension Year: 2008 TRAM-34 ameliorates hypoxia-induced pulmonary arterial hypertension in rats Source: Annual Congress 2013 –Pulmonary circulation: animal models and experimental treatments Year: 2013 Sildenafil treatment for portopulmonary hypertension Source: Eur Respir J 2006; 28: 563-567 Year: 2006